Objective: During cardiopulmonary bypass, inflammation and immunosuppression is present. We measured circulating mediators and monocyte-based functions and tested the hypothesis that these variables are influenced by methylprednisolone (MP) or tirilazad mesylate (TM) treatment.
C ardiopulmonary bypass (CPB) is known to be associated with significant perioperative inflammatory stress reactions. Exposure of blood to nonphysiological surfaces, reperfusion of organs after ischemia, release of endotoxin, and hypothermia have all been demonstrated to lead to an inflammatory response. Exaggerated proinflammatory reactions are thought to be associated with postoperative complications (1) . It has become clear that after major surgery anti-inflammatory systems are even more strongly activated (2) . Moreover, the anti-inflammatory response rather than the presence of proin-flammatory mediators has been shown to determine fatal outcome in infection (3) , and cardiac surgery is known to be associated with higher infection rates compared with other surgical procedures (4) . The inflammatory reaction to CPB is critically related to immunologic functions of leukocytes, and, during the course of immune activation, monocyte functions represent key elements as these cells are able to secrete a spectrum of cytokines, which ultimately may determine immune function. Among others, circulating lipopolysaccharides (LPS) from bacterial sources have been implicated as a source of immune activation during CPB procedures (5) . LPS binds monocyte CD14 thereby inducing tumor necrosis factor (TNF)-␣ synthesis. The central role of monocytes in regulating immune functions may also be represented by their potency to interact with lymphocyte Tcell receptors via human leukocyte antigen (HLA)-DR-mediated antigen expression. Conceptually, T-cell activation may be diverted into distinct, mutually exclusive types. Th1 type of lymphocyte helper cell activation is supported by interleukin (IL)-12 produced by activated monocytes and production of interferon (IFN)-␥, which inhibits Th2 response type and activates monocytes. On the other hand, Th2 type of lymphocyte function can be characterized by IL-10 production, which suppresses Th1 type.
To reduce proinflammatory actions, glucocorticoid drugs are widely used. The overall influence of this treatment on monocyte-based functions is ill defined. Glucocorticoids are known to have both genomic and nongenomic effects. The latter may become apparent at higher concentrations within minutes but functional consequences are much less well known (6) . Newly designed anti-inflammatory drugs include aminosteroids, which are thought to lack genomic action with preserved nongenomic effects (7, 8) . An absence of immunodepression of aminosteroid drug therapy has only been shown in vitro (9) .
The purpose of this study, therefore, was to investigate how inflammatory mediators and monocyte-based functions are altered during the course of routine CPB and whether the treatment with different steroids alters monocyte functions.
METHODS
Patients. After approval of the local ethics committee and written informed consent, 39 patients (5 female and 34 male) were enrolled in a prospective, randomized trial to investigate whether preoperative application of methylprednisolone (MP, n ϭ 13) or tirilazad mesylate (TM, n ϭ 13) may reduce inflammatory markers and immune function compared with placebo treatment (PL, n ϭ 13). Entry criteria included patients with three-vessel disease older than 18 yrs with stable angina pectoris, left ventricle ejection fraction (LVEF) Ն0.4, left ventricular end diastolic pressure Ͻ17 mm Hg, absence of preexisting pulmonary diseases (determined by clinical examination, chest radiography, lung function tests, and blood gas analyses), absence of insulindependent diabetes mellitus, and clinically relevant renal, hepatic, or cerebrovascular disease. Patients with preoperative signs of infection (like white cell blood count Ͼ12,000/L, body temperature Ͼ38°C, Creactive protein Ͼ5 mg/dL), chronic inflammatory diseases, or those treated with either cyclooxygenase inhibitors, steroids, or lazaroids within 7 days before the operation were excluded. Patients admitted for emergency surgical intervention were also excluded. All patients survived the operation procedure to leave the hospital.
Patients were randomized to receive either MP (Urbason, 15 mg/kg body weight), TM (Freedox, 10 mg/kg body weight), or PL in equal volumes within 1.5 hrs before extracorporeal circulation. One patient accidentally was treated with both MP and TM and therefore had to be excluded from data analysis.
Anesthesia Management. After oral premedication with 0.1 mg/kg midazolam, all patients had standardized general anesthesia. Intravenous induction was performed with 2 g/kg sufentanil and 0.1 mg/kg pancuronium, followed by a continuous infusion of 1-2 g/ kg/hr sufentanil, repetition boluses of 0.07 mg/kg midazolam, and 0.05 mg/kg pancuronium as needed. All patients were ventilated with an oxygen-air mixture (FIO 2 0.5) to maintain an end tidal PCO 2 of 35-45 torr. A pulmonary artery catheter (Opticath-catheter, P7110-E, Abbott Laboratories, Wiesbaden, Germany), a peripheral artery catheter (18 G Leader Cath, Vygon, Ècouen, France), and a urinary catheter with tip thermistor were inserted.
Cardiopulmonary Bypass Management.
Before CPB, 350 U/kg heparin (Liquemin, Hoffmann-La-Roche, Grenzach-Wyhlen, Switzerland) and additional boluses of 50 U/kg were given if necessary to maintain an activated clotting time of at least 480 secs. During the operative procedure, all patients received aprotinin (Trasylol, 50,000 IE/kg, Bayer, Leverkusen, Germany). Routine CPB priming included HES 10% (500 mL, Fresenius Kabi, substitution grade 0.4 -0.55, mean MW 200,000), electrolyte solution (Thomaejonin, 500 mL, Delta Pharma GmbH, Pfullingen, Germany), and heparin (8000 U). CPB was performed under slightly hypothermic conditions (34.5-35.5°C) using a membrane oxygenator (Quadrox, Jostra, Hirrlingen, Germany) and centrifugal pump flows (Bio-Medicus, Medtronic, Indianapolis, IN) adjusted to 120% of the calculated cardiac index of 2 L/min/m 2 ).
Measurements. Blood samples were collected from the cannulated radial artery 20 mins after induction of general anesthesia (time point 1), 1 hr (time point 2) and 4 hrs after cross-clamp release (time point 3), and on the first postoperative morning (time point 4). Serum and plasma of these samples were immediately stored at -80°C for later analysis.
IL-6, IL-8, IL-10, monocyte chemoattractant protein (MCP)-1, tumor necrosis factor (TNF)-␣, IL-1 receptor antagonist (IL-1RA), interferon (IFN)-␥, IL-12 p75 heterodimer (IL-12), and transforming growth factor (TGF)-␤1 concentrations in serum or supernatants were determined using enzyme-linked immunoassays obtained from DPC Biermann GmbH, Bad Nauheim, Germany (Milenia IL-6, sensitivity: 4 pg/mL; Milenia IL-8, sensitivity: 5 pg/mL; Milenia IL-10, sensitivity: 3 pg/mL; Milenia TNF-␣, sensitivity: 6 pg/mL); R&D Systems, Wiesbaden, Germany (Quantikine IL-1RA, IL-12 HS, and TGF-␤ with sensitivities of 14 pg/mL, 0.5 pg/mL, and 7 pg/mL, respectively); and PerSeptive Diagnostics, Framingham, MA (Titerzyme IFN-␥, sensitivity: Ͻ1 pg/mL), respectively. White blood cell counts (WBC) were determined using a coulter counter (Cell dyn, Abbott, Wiesbaden, Germany).
Secretion of TNF-␣, IL-1RA, IL-12, and IFN-␥ from whole blood was performed after stimulation with 100 ng/mL LPS (Escherichia coli 0127:B8; Sigma, Deisenhofen, Germany) in medium consisting of VLE-RPMI (Biochrom, Berlin, Germany) at 37°C without additional serum (10) . The supernatant was stored at -80°C and analyzed by a blinded investigator after completion of the study.
Surface expression of HLA-DR and CD14 was performed by flow cytometry using labeled monoclonal antibodies, FACScan, and Lysys II software (all from Becton Dickinson, Heidelberg, Germany), as previously described (11) .
Statistical Analysis. We tested the following null hypothesis: there is no difference in the stimulated TNF-␣ synthesis among the MP, TM, and PL groups. Differences between groups at a given time point were analyzed with Kruskal-Wallis analysis of variance (ANOVA) on ranks. To compare data from time points 2, 3, and 4 with time point 1 within groups, the Friedman repeated measures ANOVA on ranks was used. Dunn's post hoc multiple comparison procedure was used to isolate the two treatment groups from placebo group. A p value of Ͻ.05 was considered significant.
RESULTS
Patient Characteristics. The clinical characteristics of the study groups are summarized in Table 1 . There were no statistically significant differences in age, sex distribution, body mass index, number of grafts, duration of CPB or operation, smokers, diabetics, intensive care unit stay, or hospital stay. There also were no differences in donation of blood and catecholaminergic support, fresh frozen plasma requirements, or fluid balances.
Pro-and Anti-inflammatory Markers. Typical increases in circulating IL-6, IL-8, and MCP-1 mark the inflammatory response in patients treated with PL, which were significantly depressed by MP treatment but not by TM treatment (Table 2). Compared with these proinflammatory markers, relative increases in antiinflammatory IL-10 and IL-1 RA were measured in parallel. MP treatment superinduced IL-10 release, whereas TM treatment was not different compared with PL treatment ( Table 2) . Circulating levels of TGF-␤ showed large interindividual and intraindividual variations with no clear changes ( Table 2 ). The ratio of IL-10 to IL-6 at individual maximum levels and the relative increases of putative proinflammatory cytokines (IL-6 ϩ IL-8) compared with relative increases in antiinflammatory cytokines (IL-10 ϩ IL-1RA) are given in Figure 1 .
Monocyte Counts and Surface Expression of HLA-DR and CD14. Monocyte counts increased continuously during the perioperative course from 0.43 Ϯ 0.27 gigaparts (Gpt)/nL to 0.61 Ϯ 0.39 Gpt/L in the PL group, from 0.36 Ϯ 0.19 Gpt/L to 0.60 Ϯ 0.47 Gpt/L in the MP group, and significantly from 0.34 Ϯ 0.15 Gpt/L to 0.86 Ϯ 0.69 Gpt/L (p Ͻ .05) in the TM group. On the other hand, relative HLA-DR expression decreased from 91.9 Ϯ 6.6% to 67.1 Ϯ 19.2% (p Ͻ .05) in patients treated with PL, from 89.2 Ϯ 7.8% to 46.4 Ϯ 18.9% (p Ͻ .05) in patients treated with MP, and from 91.2 Ϯ 6.6% to 64.6 Ϯ 11.8% (p Ͻ .05) in patients treated with TM. Compared with the PL group, a significant lower postoperative HLA-DR expression was measured in MP patients (p Ͻ .05), whereas there was no statistically significant difference in patients treated with TM.
Monocyte CD14 expression slightly decreased in PL patients by 13 Ϯ 34% Figure 1 . Ballanced pro-and anti-inflammatory reactions during coronary artery bypass graft operations. A, the ratio of interleukin (IL)-10 to IL-6 is given before, during, and after the operation in patients treated with placebo (PL, white circles), methylprednisolone (MP, black circles), and tirilazad mesylate (TM, black squares). B, maximum relative increases of proinflammatory markers (IL-6 and IL-8) and maximum relative increases in anti-inflammatory markers (IL-10 and IL-1RA) are shown. Values given are mean Ϯ SEM; §p Ͻ .05 compared with placebo-treated group.
(not significant). CD14 expression increased slightly in MP patients by 1 Ϯ 35% (not significant) and in TM patients by 13 Ϯ 38% (not significant).
Ex vivo TNF-␣, IL-1RA, IFN-␥, and IL-12 Secretion. LPS-stimulated secretion of TNF-␣ in PL-treated patients significantly decreased 4 hrs after aortic declamping compared with baseline values (from 793 Ϯ 382 pg/mL to 183 Ϯ 143 pg/mL; p Ͻ .05) and did not recover until the first postoperative day (512 Ϯ 278 pg/mL). Patients receiving MP showed LPS-stimulated TNF-␣ secretion decreasing from 692 Ϯ 366 pg/mL preoperatively to 85 Ϯ 40 pg/mL and remained significantly lower than in PL group on the first postoperative day (225 Ϯ 183 pg/mL; p Ͻ .05). TNF-␣ secretion of patients treated with TM paralleled the course of placebo-treated patients (897 Ϯ 353 pg/mL, 144 Ϯ 83 pg/mL, and 524 Ϯ 288 pg/mL on time points 1, 3, and 4, respectively; Fig. 2A ).
LPS-induced IL-1 RA secretion in PL was 12.4 Ϯ 6.3 ng/mL, 23.9 Ϯ 16.8 ng/mL, and 21.8 Ϯ 9.1 ng/mL at time points 1, 3, and 4, respectively. MP-treated patients had stimulated IL-1RA secretion of 11.1 Ϯ 9.6 ng/mL, 16.4 Ϯ 6.1 ng/mL, and 20.7 Ϯ 12.8 ng/mL at time points 1, 3, and 4, respectively. Statistically significant increases in IL-1RA secretion from 12.2 Ϯ 5.8 ng/mL at time point 1 to 19.0 Ϯ 6.0 ng/mL at time point 3 (p Ͻ .05) and 27.6 Ϯ 11.3 ng/mL at time point 4 (p Ͻ .05) were measured in TM-treated patients (Fig. 2B) .
IFN-␥ secretion showed marked basal variability (PL: 338 Ϯ 524 pg/mL; MP: 107 Ϯ 135 pg/mL; TM: 175 Ϯ 381 pg/mL) and rapidly decreased to almost undetectable levels in all patients regardless of the treatment (Fig. 3A) .
LPS-stimulated secretion of IL-12 decreased from 13.8 Ϯ 17.5 pg/mL preoperatively to 2.4 Ϯ 1.9 pg/mL (p Ͻ .05) and to 1.8 Ϯ 1.9 pg/mL (p Ͻ .05) at time points 3 and 4, respectively, in PL patients. Patients treated with MP or TM also showed decreased LPS-stimulated ex vivo secretion of IL-12 (MP: 12.3 Ϯ 13.8 pg/mL, 1.1 Ϯ 0.8 pg/mL, 1.3 Ϯ 1.1 pg/mL; TM: 10.1 Ϯ 6.5 pg/mL, 2.3 Ϯ 1.9 pg/mL, 2.1 Ϯ 1.3 pg/mL at time points 1, 3, and 4, respectively), which statistically was not different from the PL group (Fig. 3B ).
DISCUSSION
On one hand, an immune activation after major surgery has generally been considered to be reflected by the systemic release of proinflammatory mediators like IL-8 or IL-6, which also has antiinflammatory functions. An exaggeration of this response may predispose patients to deleterious consequences such as sepsis and end-organ failure. In the past, it has been shown that together with the release of proinflammatory mediators anti-inflammatory systems are activated leading to the hypothesis that the disruption of the balance between the systemic inflammatory response syndrome and the compensatory anti-inflammatory response syndrome determines outcome. Maximum circulating levels of proinflammatory markers IL-6 and IL-8 have been reported to be found approximately 4 hrs after cross-clamp release. In line with these reports, IL-6 and IL-8 increased 110 times and 1.8 times, respectively. However, maximum circulating anti-inflammatory IL-10 has been reported to be released even earlier. At the end of the surgical procedure, circulating IL-10 increased 90 times the preoperative value and IL-1 RA increased by a factor of 71. Calculating a simple ratio between IL-10 and IL-6 or the sum of maximum increases in proinflammatory markers IL-6 and IL-8 compared with maximum increases in anti-inflammatory markers IL-10 and IL1-RA demonstrates that it physiologically remains stable along an uncomplicated operative course (Fig. 1) . All patients were treated with aprotinin. This serine protease inhibitor clearly has antiinflammatory potencies (12) , but the inflammatory response still was present. According to the standard definition (13), 10, 7, and 9 patients treated with PL, MP, and TM, respectively, postoperatively developed a systemic inflammatory response syndrome with no significant difference.
On the other hand, an immune activation at the cellular level is necessary to clear an infection. The development of an adequate immune response to a bacterial challenge relies on the complex interplay between the innate and the specific immune system reflected by intact monocyte-T-cell-neutrophil interactions. Monocyte and macrophage functions include the recognition, uptake, and killing of invading organisms to initiate an immune response. This initiation may be accomplished by secretion of proinflammatory mediators like TNF-␣, IL-12 and IL-1, and a direct antigen-presenting capacity reflected by the expression of, for example, HLA-DR. These monocyte functions are up-regulated by immunostimulatory cytokines like IFN-␥ and suppressed by IL-10 and TGF-␤, for example.
Patients in the PL group showed significant postoperative depression of LPS-stimulated TNF-␣ secretion that was not accompanied by a decrease in IL-1RA secretion, indicating a functional switch rather than a general secretory depression. This is also supported by the finding that CD14 expression, which is the major receptor for LPS, was not altered during the study. Stimulated secretion of IL-12, which supports differentiation and function of Th1 cells as well as IFN-␥, which typically is released from Th1 cells and activates monocytes to support cell-mediated immune responses, was completely diminished and indicates a reduced type 1 of cell-mediated immune function. T-cellbased functional tests have many times been shown to be depressed in patients after cardiac surgery corresponding with type 1 T-cell response deficits (14) . A decrease in HLA-DR-expressing monocytes was noted in our patients, consistent with earlier reports (15) . Again, these findings support decreases in antigen-presenting functions of monocytes. The present study was not powered to detect a difference in infectious complications as a clinically important outcome, however, monocyte functional deficits have been shown to be closely related to the development of postoperative sepsis (16, 17) . In fact, after major injury or major surgery, and during sepsis, severe lymphocyte and monocyte functional depression is known to occur, leaving the possibility that cellular functional depressions rather than an overactivation determines perioperative outcome.
Treatment with MP reduced proinflammatory markers IL-6, IL-8, and MCP-1, whereas anti-inflammatory IL-10 was superinduced by a factor of 220 and circulating IL-1RA secretion was unaffected. Calculating the IL-10/IL-6 ratio or relative maximum increases in pro-and anti-inflammatory cytokines in MPtreated patients shows a dramatic shift toward an anti-inflammatory state (Fig.  1 ). MP treatment also aggravated monocyte functional deficits. The already de- creased LPS-stimulated TNF-␣ secretion 4 hrs after cross-clamp release became significant on the first postoperative day, and lowest HLA-DR expression was found in this group. To our knowledge, this glucocorticoid-mediated depression has so far only been shown in in vitro models (9, 18) . Glucocorticoids depress monocyte functions during CPB and may therefore increase infection rates. These may become apparent only in larger series, as cellular depression is already present.
TM is an aminosteroid drug that has been developed to reduce genomic effects of glucocorticoids while preserving membrane effects (9) . This drug has largely been studied in ischemia reperfusion injury of neuronal tissue and proved as an efficient treatment (19) . Cardioplegic coronary surgery can be regarded as a controlled model of ischemia and reperfusion to the heart and data from human studies after aminosteroid pretreatment are scarce. Absence of immunocompromising effects of this drug has been mainly inferred from in vitro studies (9) and the higher sepsis and pneumonia rates in patients treated with highdose MP or TM after spinal trauma in National Acute Spinal Cord Injury Study III (20) . Reperfusion of organs and CPB may independently be associated with an inflammatory response. Anti-inflammatory activity of aminosteroid drugs was inferred from animal studies demonstrating, for example, reduced proinflammatory gene expression in renal ischemia and reperfusion (8) , reduced IL-6 and TNF-␣ levels in pulmonary mononuclear cells of mice after hemorrhage and resuscitation (7) , or an improved vascular response of acute inflammation (21) . In patients treated with TM, no significant alteration in the release of IL-6, IL-8, MCP-1, IL-10, or IL-1 RA was measured, suggesting that, in the current setting, this drug has no anti-inflammatory action. Secretory monocyte functions and expression of HLA-DR was also not different from the PL group, demonstrating that this drug leads to no additional immunosuppression. Prebypass single infusion of TM was not associated with an obvious clinical benefit in this small study. An antiinflammatory effect during routine CPB by this antioxidant may need higher dosages and longer treatment times to show clinical improvements in larger series of patients.
Taken together, the presented data show that routine CPB is associated with a balanced inflammatory reaction. Tremendous monocyte depression quantifiable by structural (loss of HLA-DR ex-pression) and functional parameters (decreased LPS-stimulated TNF-␣ and IL-12 release) is present. The early release of IL-10 together with an almost complete loss of stimulated IL-12 and IFN-␥ secretion promotes the depression of TH1 type of cell-mediated immunity. Prebypass high-dose MP treatment aggravated monocyte depression, probably because of its potency to superinduce IL-10 in vivo. Taking into account the absence of significant hemodynamic benefit and the questionable benefit of reducing proinflammatory markers in routine CPB, we feel that this treatment is likely to cause an additional risk of infection, whereas TM was neither anti-inflammatory nor immunosuppressing.
